Codexis(US:CDXS)2026-03-11 20:39Manufacturing Capabilities - The ECO Synthesis manufacturing platform enables large-scale manufacture of RNA interference (RNAi) therapeutics, with the potential to produce tens to a hundred kilograms of high-purity RNA per run[16]. - The current industry standard for RNAi therapeutics manufacturing is limited to single-digit kilogram synthesis batch sizes, presenting challenges in scalability and quality control[20]. - The ECO Synthesis manufacturing platform can produce tens to a hundred kilograms of high-purity RNA per run, significantly increasing scalability compared to traditional SPOS methods limited to single-digit kilogram batch sizes[21]. - The ECO Synthesis platform mitigates the need for high volumes of acetonitrile, significantly reducing chemical waste streams and disposal costs[21]. - The ECO Synthesis manufacturing platform allows for the production of RNAi sequences and modifications, enhancing targeted tissue delivery capabilities[23]. - The ECO Synthesis Innovation Lab was completed at the end of 2024, enabling the optimization of manufacturing processes for specific siRNA assets before technology transfer to CDMO partners for GMP-grade production[22]. - The company completed the build-out of its ECO Synthesis Innovation Lab, capable of synthesizing gram-scale quantities of siRNA suitable for pre-clinical testing[16]. - In 2025, the company successfully manufactured non-GMP-grade siRNA drug substance for customers under development services contracts[16]. Partnerships and Collaborations - The company entered partnerships with three large-scale contract development and manufacturing organizations (CDMOs) to evaluate the ECO platform for synthesizing GMP-grade siRNA drug substance[16]. - The company anticipates signing additional partnerships with CDMOs to provide enzymatically synthesized GMP-grade siRNA material to drug developer customers by 2026[45]. - The company has entered into various licensing agreements, including a December 2024 agreement with Pfizer for enzyme manufacturing, which includes potential milestone payments[33]. - Codexis is eligible to receive future development and commercial milestone payments from Crosswalk Therapeutics for investigational compounds related to Fabry and Pompe diseases[39]. Market and Demand - The company anticipates significant growth in worldwide demand for RNAi therapeutics as clinical development progresses and more assets are commercially approved[19]. - The RNAi pipeline is shifting focus from rare conditions to high-prevalence diseases like Alzheimer's and hypertension, indicating a significant growth opportunity[19]. - As of December 31, 2025, there were eight approved siRNA therapeutics on the market in the U.S., with hundreds of RNAi therapeutic assets in development, including 41 in Phase 2 and Phase 3 clinical trials[19]. Financial and Revenue Insights - One customer accounted for approximately 51% of the company's total revenues for the year ended December 31, 2025[53]. - The company is dependent on a limited number of customers, which poses a risk to its revenue stability[12]. - The company expects to rely on third-party manufacturers for commercial production of biocatalysts for the foreseeable future[54]. Research and Development - The company has reduced its emphasis on new projects in small-molecule biocatalysis due to decreased pricing opportunities in the broader enzyme market[30]. - The small molecule pharma biocatalysis business utilizes the CodeEvolver technology platform to develop optimized enzymes, improving manufacturing efficiency for small molecule therapeutics[17]. - The company has invested significantly in the development of the CodeEvolver technology platform since 2002, which is a key competitive advantage[18]. - The company monitors developments in directed molecular evolution and computational design to stay competitive in enzyme engineering[51]. Workforce and Corporate Responsibility - As of December 31, 2025, the company had 146 full-time and part-time employees, with 45 engaged in research and development[62]. - The company is committed to maintaining a safe and healthy workplace, adhering to environmental, health, and safety regulations[60]. - The company is committed to diversity, equity, and inclusion, ensuring recruitment without discrimination based on gender, ethnicity, or other traits[64]. - The company maintains a focus on health and safety, implementing policies to protect employees and surrounding communities[65]. Intellectual Property - As of December 31, 2025, the company owned approximately 1,600 active patents and pending applications, with terms expiring between 2026 and 2046, supporting its proprietary technologies[42]. - The company continues to file new patent applications, with terms generally extending 20 years from the non-provisional filing date in the United States[42]. - The company has approximately 92 trademark registrations in the United States and foreign jurisdictions as of December 31, 2025[43]. Corporate Structure and History - The company was incorporated in Delaware in January 2002 and commenced independent operations in March 2002 after licensing technology from Maxygen, Inc.[66]. - The company has consolidated operations to its Redwood City headquarters and discontinued investment in biotherapeutics as part of a restructuring announced in July 2023[54]. Competitive Landscape - The market for supplying enzymes for pharma biocatalysis is fragmented, with competition from large industrial enzyme companies and smaller firms[49]. - The company faces competition from existing in-house technologies within client companies, as well as from companies developing conventional catalysts[47]. - The company’s core technology relies on enzyme engineering, with significant competition from other companies and academic institutions in this field[50].